Allicin inhibits kidney stone formation by suppressing the TNF/NF-κB pathway: Experimental validation through network pharmacology, in vitro, and in vivo studies Authors: Zechun Peng, Mingbin Xu, Jie Yang, Shuming He Published: 2026 ABSTRACT AbstractBackground and ObjectiveNephrolithiasis is a prevalent urological disorder characterized by significant incidence and frequent recurrence. Allicin has diverse pharmacological effects; however, its precise function and underlying mechanisms in reducing kidney stone formation have not been thoroughly investigated. The present research endeavors to comprehensively examine the impact of allicin on the development of renal calculi and elucidate its underlying mechanisms.MethodsA multifaceted methodology was implemented, incorporating network pharmacology for target and pathway identification, molecular docking to evaluate binding affinities, in vitro experiments utilizing calcium oxalate-damaged HK-2 cells for assessing cellular responses, and in vivo investigations employing ethylene glycol-induced nephrolithiasis rat model to examine physiological impacts.ResultsIntegrated network pharmacological screening identified 46 overlapping targets shared by allicin and nephrolithiasis. Among these hub molecules, TNF was recognized as the central effector target, and the TNF/NF‑κB signaling axis was determined as the dominant pathway mediating the protective effects of allicin against renal crystal formation. Molecular docking confirmed that allicin moderately binds to TNF (binding energy of -2.05 kcal/mol). In vitro, allicin (200 µmol/L) improved the viability of injured HK-2 cells and decreased the levels of inflammatory factors. In vivo, allicin reduced kidney damage and calcium oxalate deposition in rats.ConclusionAllicin alleviates kidney stones by inhibiting the TNF/NF-κB pathway, providing preclinical evidence for its potential in kidney stone management.Clinical Trial RegistrationNot applicable.Supplementary InformationThe online version contains supplementary material available at 10.1007/s11033-026-12089-y.Keywords: Kidney stones, Allicin, TNF/NF-κB pathway, Network pharmacology, Animal model Introduction Kidney stone disease, also termed nephrolithiasis, is a highly prevalent urological disorder with a substantial global impact. It affects approximately 12% of the world’s population, and its incidence has been increasing in recent decades, particularly in developed countries [1]. Nephrolithiasis predominantly presents in patients aged 20 through 60 years, with respective recurrence rates of approximately 50% at 5–10 years and 75% at 20 years after initial onset [2]. Kidney stones are linked to an elevated risk of end-stage renal failure, along with other systemic disorders, including diabetes, cardiovascular disease and bone fractures [1]. Kidney stone formation is attributed to multiple etiological factors, including genetic, environmental, and lifestyle factors. Calcium oxalate is the most prevalent type of kidney stone, and it frequently develops on Randall’s plaques located on the surfaces of renal papillae [3]. Cellular injury, induced by factors such as oxidative stress and inflammation, can promote the retention of particles on renal papillary surfaces, contributing to stone formation [4, 5]. There is significant diversity in the therapeutic approaches used for treating renal calculi. In cases of small stones (typically under 6 mm in diameter) that do not present notable symptoms, obstructions, or infections, a watchful waiting strategy combined with conservative treatment is frequently advised. This approach primarily involves augmenting fluid consumption (daily intake of 2000–3000 ml of water to increase urine production and aid in stone expulsion) along with moderate physical activity [6]. Various surgical interventions are frequently employed for stone management, such as extracorporeal shock-wave lithotripsy (ESWL) for calculi under 2 cm, percutaneous nephrolithotomy for larger or more intricate stones, and ureteroscopic lithotripsy for smaller renal and ureteral calculi [7]. Drug therapy plays a crucial role in the management of kidney stones. For example, in cases of renal colic pain, nonsteroidal anti-inflammatory drugs (NSAIDs), such as indomethacin, and opioids, such as morphine, are used to relieve pain. When there is an associated urinary tract infection, antibiotics such as cephalosporins (e.g., cefixime) and fluoroquinolones (e.g., levofloxacin) are prescribed [7]. To promote stone expulsion, alpha-blockers such as tamsulosin can be used, as they help relax the smooth muscles of the ureter, facilitating the passage of stones [8, 9]. For specific types of stones, there are corresponding dissolution drugs. For pure uric acid stones, medications such as potassium sodium hydrogen citrate and sodium bicarbonate can be used to alkalize the urine and dissolve the stones, whereas acetylcysteine can be used for cystine stones [10, 11]. However, drug treatment has limitations. The effectiveness of drug-induced stone dissolution is often limited to small stones, and long-term use of some drugs may lead to side effects. For example, long-term use of potassium citrate may cause abdominal pain and other gastrointestinal discomfort, and the use of some diuretics may lead to electrolyte imbalances [12, 13]. Natural compounds have attracted increasing attention in this regard. Numerous studies have explored the protective and therapeutic effects of dietary plants and their bioactive constituents against kidney stone disease [14, 15]. For example, caffeine, a natural xanthine alkaloid, has been reported to have a dual effect on kidney stone formation, with some studies suggesting its potential to lower the likelihood of kidney stone formation by impairing the capacity of calcium oxalate to adhere to renal epithelial cells [14]. Calycosin and formononetin have been confirmed to ameliorate renal injury by regulating oxidative stress, inflammation, apoptosis and fibrotic processes in the kidney [16, 17]. Epigallocatechin-3-gallate (EGCG), the main bioactive component in green tea, has also been shown to have an inhibitory effect on kidney stone formation by reducing oxidative stress and inhibiting the membrane translocation of proteins related to calcium oxalate crystal binding in renal epithelial cells [18, 19]. Among these natural compounds, allicin, a sulfur-containing compound derived from garlic, has been well documented to exert anti-inflammatory, antioxidant and renoprotective effects, making it a promising natural agent for the prevention and treatment of nephrolithiasis [20]. In recent years, network pharmacology and molecular docking have been increasingly applied in biomedical research. Network pharmacology serves as a systematic strategy that combines systems biology and multi-dimensional omics data to map molecular interaction networks. This approach allows comprehensive dissection of the complex links between natural compounds, their potential targets, and disease-related pathways, providing a holistic basis for mechanistic research [21]. This approach facilitates the identification of key targets and relevant pathways by analyzing overlapping molecules from multiple databases, providing a holistic perspective for understanding biological processes. In addition, molecular docking, a computational approach, predicts the binding affinity and interaction modes between ligands and target proteins, verifying potential molecular interactions through simulating three-dimensional structures and calculating binding energies [22]. Together, these techniques have become powerful tools in fields such as drug discovery, mechanism exploration of natural products, and functional analysis of bioactive compounds, offering efficient and reliable theoretical support for in-depth biomedical investigations. Although allicin exhibits anti-inflammatory and cytoprotective effects, its role and mechanism in mitigating nephrolithiasis remain poorly clarified. Current research only preliminarily demonstrated its renal protection but failed to systematically identify its core targets and key signaling pathways, particularly the regulatory action on the TNF/NF-κB cascade in calcium oxalate-induced tubular injury and crystal deposition. Moreover, existing studies lack multi-level verification integrating network pharmacology, in vitro and in vivo experiments, and comprehensive histological evaluation including Von Kossa staining for calcium oxalate deposition. To fill this gap, we integrated network pharmacology, molecular docking, in vitro HK-2 cell assays, and in vivo experiments in ethylene glycol-induced kidney stone rats. Notably, we used hematoxylin and eosin (HE) staining (for renal injury) and Von Kossa staining (for calcium deposition) to comprehensively evaluate the effects of allicin. This study aimed to clarify whether allicin alleviates kidney stones by regulating the TNF/NF-κB pathway, providing preclinical evidence for its application and filling methodological gaps in related research. Method Network pharmacology and bioinformatics analysis The chemical structure of allicin was retrieved from PubChem. Allicin-related target genes were identified via the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP: https://www.91tcmsp.com/) and SwissTargetPrediction (http://swisstargetprediction.ch/). Kidney stone-associated targets were retrieved from the GeneCards (https://www.genecards.org/) database. Overlapping targets, representing potential targets of allicin in regulating kidney stones, were identified through intersection analysis. Cytoscape software was used to construct the allicin component‒disease target network, and the String (https://string-db.org/) database was employed to construct a protein‒protein interaction (PPI) network. R packages were utilized to conduct Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses, aiming to elucidate the associated biological processes and signaling pathways. Furthermore, AutoDock Vina was utilized to perform the molecular docking experiments. The three-dimensional structures of allicin (obtained from PubChem) and its core targets (retrieved from PDB) were preprocessed, and the most favorable complexes were subjected to molecular dynamics simulation. Materials Consumables, reagents, and instruments Detailed information on consumables, reagents and instruments is provided in the Supplementary Materials. Animals A total of 12 healthy adult male Sprague-Dawley (SD) rats, weighing 200 ± 20 g, were maintained under specific pathogen-free conditions and randomly assigned into four groups with 3 rats per group (n = 3). Prior to the commencement of the experiments, the rats were acclimatized for a period of one week while being housed in a temperature-controlled environment (22 ± 2 °C) with a 12-hour light/dark cycle, with ad libitum access to standard chow and distilled water. The experimental protocol was approved by the Ethics Committee of Hainan Medical University (Approval No. HYLL-2024-614). All animal experiments were performed in accordance with the relevant guidelines and regulations for the care and use of laboratory animals. Cell culture and model establishment Human renal tubular epithelial cells (HK-2) (CL-0109, Procell, China) were maintained in a 5% CO2 incubator at 37 °C and cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin‒streptomycin. By treating HK-2 cells with 20 mmol/L sodium oxalate for 12 h, a renal injury cell model induced by calcium oxalate crystals was successfully established. The high concentration of 20 mmol/L sodium oxalate was used to simulate the cumulative long-term hyperoxaluric damage to renal tubular cells in vivo as an accelerated microenvironmental insult within a limited in vitro experimental duration. Experimental groups and treatments The cells were assigned to several experimental groups as follows: (1) the control group (no intervention); (2) the model group (treated with 20 mmol/L sodium oxalate for 12 h); (3) the allicin groups (treated with 50, 100, 200, 400, 800, or 1600 µmol/L allicin for 24 h after modeling); (4) the allicin + TNF group (treated with allicin and exogenous TNF after modeling); and (5) the TNF inhibitor group (treated with the TNF inhibitor etanercept at a concentration of 1 µg/ml after modeling). Enzyme-linked immunosorbent assay (ELISA) The cell samples were lysed, and ELISA was performed strictly according to the manufacturer’s instructions. The absorbance was measured at 450 nm. Western blot analysis After being washed with PBS, the treated cells were lysed in ice-cold RIPA buffer containing PMSF and subsequently centrifuged at 12,000 × g (4 °C, 5 min) to obtain the supernatant for further analysis. A BCA assay was used to determine the protein concentration, after which the protein samples were subjected to SDS‒PAGE and subsequently transferred onto methanol-activated PVDF membranes. At room temperature, the membranes were blocked and subsequently incubated overnight at 4 °C with primary antibodies specific for TNF, TNFR1, NF-κB, p-NF-κB, IL-1β, IL-18, IL-6 (1:1000) and GAPDH (1:6000), after which they were incubated with HRP-conjugated secondary antibodies (1:6000). The visualization of protein bands was achieved through enhanced chemiluminescence (ECL), followed by quantification via ImageJ, with the relative protein expression being determined as the ratio of the target protein to GAPDH. CCK-8 assay The cells were seeded in 96-well plates at 2000 cells/well, allowed to attach for 4–8 h, and then treated in groups (6 replicates per group). CCK-8 solution (10 µL) was added 2 h prior to incubation, and the absorbance was measured at 450 nm. TUNEL assay The TUNEL assay was performed following the kit instructions to assess chromatin integrity. In vivo experiments Animal grouping and model establishment The blank control group (A) received daily intraperitoneal normal saline injections for 21 days; the model group (B) was given daily intraperitoneal injections of 1% ethylene glycol and 1% ammonium chloride mixed solution (0.5 mL/100 g each) for 21 days to induce kidney disease; the allicin group (C) underwent the same model induction as group B plus daily intragastric allicin (50 mg/kg) for 21 days; the positive control group (D) received the same model induction as group B along with daily intragastric positive drug for 21 days. Sample acquisition and histological staining procedures After 21 days of intervention, the rats were anesthetized via an intraperitoneal injection of pentobarbital sodium (40 mg/kg body weight), and the bilateral kidneys were rapidly dissected. The left kidney was fixed in 4% paraformaldehyde for 24 h, dehydrated in gradient ethanol, cleared in xylene, embedded in paraffin, and sectioned into 4 μm slices. For HE staining, the sections were deparaffinized, rehydrated, stained with hematoxylin and eosin, dehydrated, cleared, mounted with neutral gum, and observed under a Zeiss light microscope. For Von Kossa staining, the sections were dewaxed, rehydrated, incubated with Von Kossa silver solution under strong light for 40 min, treated with Hypossa solution, counterstained with Van Gieson, dehydrated, cleared, and mounted with neutral balsam. Statistical analysis Statistical evaluations were performed via GraphPad Prism software, and all the results are reported as the means ± SDs with appropriate statistical significance. Statistically significant group differences were examined through Student’s t test or one-way ANOVA, with a P value threshold set at less than 0.05 indicating significance. Results Allicin targets, pathways and TNF-binding affinity in kidney stone regulation Network pharmacology identified 46 overlapping targets between allicin and kidney stone-related genes (Fig. 1A); the PPI network (Fig. 1B) pinpointed core targets (TNF, EGFR, and IL6). GO enrichment (Fig. 1C) covered processes (xenobiotic response, apoptosis regulation), components (collagen extracellular matrix) and functions (chaperone binding); KEGG analysis (Fig. 1D) highlighted pathways such as “microRNAs in cancer” and “TNF signaling pathway”. Molecular docking (Fig. 1E) confirmed that allicin binds to the active pocket of TNF (residues LYS-65/LEU-142/PHE-144, 1.8/3.2/2.0 Å interactions), with a binding energy of -2.05 kcal/mol, indicating a moderate binding interaction between allicin and TNF. Network pharmacology and molecular docking analysis of allicin in kidney stone regulation (A: Venn diagram of allicin-kidney stone overlapping targets; B: PPI network; C: GO enrichment analysis; D: KEGG pathway enrichment analysis; E: Molecular docking of allicin with TNF) Allicin regulates HK-2 cell function in sodium oxalate injury via the TNF pathway First, the CCK-8 assay (Fig. 2A) was used to determine the optimal allicin concentration: compared with the model group (cell viability = 0.379), the 200 µmol/L allicin (Allicin Group 3) group had the greatest effect on cell viability (0.946, P < 0.001), so this concentration was selected for subsequent experiments. Further CCK-8 detection (Fig. 2B) revealed that the viability of the model group (0.343) was lower than that of the control group (1.000); the viability of the allicin group (0.850, P < 0.001) and the TNF inhibitor group (0.867, P < 0.001) was greater than that of the model group, whereas the viability of the allicin + TNF group (0.344) was similar to that of the model group. As revealed by TUNEL staining (Fig. 2C), the model group exhibited a significantly greater number of apoptotic cells than the control group did, whereas both the allicin group and the TNF inhibitor group demonstrated a marked reduction in apoptosis (P < 0.001). Notably, the allicin + TNF group sustained a high level of apoptosis, which was consistent with the model group. As shown in Fig. 2D and E, the model group presented increased levels of intracellular Ca2+ and inflammatory factors. Allicin and the TNF inhibitor reduced Ca2+ and inflammation (P < 0.01), while allicin + TNF reversed these effects. These results indicate that allicin can improve viability, inhibit apoptosis, and reduce intracellular Ca2+ and inflammatory factor release in sodium oxalate-injured HK-2 cells and that this effect is likely mediated by TNF inhibition. In vitro functional assays revealed that allicin improved viability, inhibited apoptosis, reduced intracellular Ca2+, and attenuated the levels of the inflammatory factors IL-6, IL-1β, and IL-18 via TNF-α regulation (A: CCK-8 for allicin concentration screening; B: CCK-8 for group comparison; C: TUNEL assay for apoptosis; D: Intracellular Ca²⁺ concentration; E: ELISA for the concentrations of the inflammatory factors IL-6, IL-1β, and IL-18; *P < 0.05, **P < 0.01, ***P < 0.001 vs. the model group) Allicin inhibits the TNF/NF-κB pathway in sodium oxalate-injured HK-2 cells by reducing TNF/TNFR1 expression and NF-κB phosphorylation (transcriptional and protein levels) in vitro Compared with those in the control group, the TNF, TNFR1, p-NF-κB/NF-κB ratio, and IL-1β, IL-18 and IL-6 protein levels in the model group were significantly elevated at the protein level (Fig. 3A-B). Compared with the model group, the allicin group had significantly lower TNF (P < 0.001), TNFR1 (P < 0.01), p-NF-κB/NF-κB (P < 0.05), IL-18 (P < 0.001) and IL-6 (P < 0.05) levels, whereas the IL-1β level was not significantly different between the allicin group and the model group. The allicin + TNF group’s levels of these indicators were close to those of the model group, with no significant difference, and the TNF inhibitor group showed significant reductions similar to those of the allicin group. Protein and mRNA expression analyses reveal that allicin inhibits the TNF/TNFR1/NF-κB pathway in sodium oxalate-injured HK-2 cells (A: Western blot protein bands; B: Relative protein expression of TNF, TNFR1, p-NF-κB/NF-κB, IL-1β, IL-6, and IL-18; C: Relative mRNA expression of TNF, NF-κB, and TNFR1; *P < 0.05, **P < 0.01, ***P < 0.001 vs. the model group) As shown in Fig. 3C, the model group presented significantly increased TNF, TNFR1, and NF‑κB mRNA expression compared with the control group. Compared with the model group, allicin markedly reduced these levels (P < 0.001 or P < 0.01). Compared with the model group, the allicin + TNF group presented higher TNFR1 mRNA levels (P < 0.05) and restored TNF/NF‑κB levels. The results of the TNF-α inhibitor group were consistent with those of the allicin group. These results indicate that allicin can reduce TNF/TNFR1 expression (at both the protein and mRNA levels) and inhibit NF-κB phosphorylation in sodium oxalate-injured HK-2 cells, thereby downregulating the expression of downstream inflammatory factors, including IL-18 and IL-6, and that this regulatory effect depends on TNF inhibition. Allicin alleviates renal tissue injury and reduces calcium oxalate deposition in ethylene glycol-induced kidney stone rats (HE and von kossa staining) The HE staining results of the renal tissues are shown in Fig. 4A. Under light microscopy, the blank control group presented clear renal tissue staining without calcium oxalate deposition, renal tubular degeneration, necrosis or inflammation. Compared with the blank control group, the model group presented extensive intratubular calcium oxalate crystal deposition, severe renal tubular degeneration and necrosis, renal interstitial inflammatory cell infiltration and renal tubular cyst formation. Compared with the model group, the allicin group and positive control group presented significant improvements in renal structure. HE and Von Kossa Staining Reveal that Allicin Alleviates Renal Tissue Injury and Reduces Calcium Oxalate Deposition in Kidney Stone Rats (A: HE Staining of Renal Tissue; B: Von Kossa Staining of Renal Tissue; a: Control Group; b: Model Group; c: Allicin Group; d: Positive Control Group) The Von Kossa staining results are presented in Fig. 4B. Under light microscopy, the blank control group displayed normal renal morphology, with no evidence of black calcium deposition. In contrast, the model group exhibited a striking accumulation of black calcium oxalate crystals, which were primarily localized to the renal tubular lumen and interstitial spaces. Compared with the model group, both the allicin treatment group and positive control group presented substantial decreases in the area of black calcium deposition and the number of calcium oxalate crystals. These observations demonstrate that allicin is capable of mitigating calcium oxalate crystal deposition within the renal tissues of kidney stone model rats. Discussion This study comprehensively evaluated the therapeutic efficacy of allicin in alleviating kidney stone formation via a multifaceted strategy that encompasses network pharmacology, molecular docking, in vitro functional assays, and in vivo animal validation. Our findings consistently demonstrate that allicin exerts antiurolithiotic effects by targeting the TNF/NF-κB signaling axis, thereby alleviating renal inflammation, tubular injury, and calcium oxalate crystal accumulation. These results not only elucidate the mechanistic basis of allicin activity but also highlight its potential as a natural therapeutic candidate for kidney stone disease. Our integrated network pharmacological strategy extracted 46 shared targets linking allicin to kidney stone pathogenesis. In the PPI network, TNF stood out as the top-ranked core node, supporting its pivotal role in the anti-inflammatory and anti-crystal mechanisms of allicin. These findings align with those of prior studies emphasizing TNF-α as a pivotal mediator of renal inflammation and crystal adhesion in nephrolithiasis [1]. As a well-established initiator of proinflammatory cascades, TNF triggers a sequence of inflammatory events, exemplified by NF-κB activation, which subsequently increases the expression of proinflammatory cytokines such as IL-1β, IL-6, and IL-18, which are critical mediators of renal tissue damage within stone-forming kidneys [23, 24]. Further confirmed by KEGG enrichment analysis, the TNF signaling pathway emerged as a significant hub, strengthening its involvement in kidney stone pathogenesis and establishing it as a pivotal therapeutic target for allicin intervention. Activation of the TNF/NF-κB axis not only triggers robust renal inflammation but also upregulates crystal‑binding proteins on the apical membrane of renal tubular epithelial cells, thereby promoting calcium oxalate adhesion, retention, and subsequent stone formation. Molecular docking confirmed a moderate binding interaction between allicin and TNF, with a binding energy of -2.05 kcal/mol, which was mediated by key amino acid residues (LYS-65, LEU-142, and PHE-144). This structural evidence supports the hypothesis that allicin directly modulates TNF activity, which is consistent with studies showing that natural compounds can inhibit proinflammatory cytokines through specific binding interactions [25, 26]. This weak-to-moderate binding interaction indicates that allicin attenuates TNF signaling rather than acting as a high-affinity competitive inhibitor, preventing its interaction with TNFR1 and subsequent activation of downstream pathways. In vitro experiments using calcium oxalate-injured HK-2 cells provided functional validation of these findings. Allicin, at an optimal concentration of 200 µmol/L, significantly improved cell viability, reduced apoptosis, and lowered intracellular Ca²⁺ levels, effects that were abrogated by exogenous TNF and mimicked by the TNF inhibitor etanercept. This reciprocal modulation confirms that allicin’s protective effects are, at least in part, mediated through TNF inhibition [27]. Western blot and q-PCR analyses further demonstrated that allicin downregulates TNF, TNFR1, and phosphorylated NF-κB, alongside reducing the levels of downstream proinflammatory cytokines (IL-1β, IL-6, and IL-18) [28, 29]. These results align with studies showing that TNF/NF-κB inhibition attenuates crystal-induced renal epithelial damage and highlight a conserved mechanism by which allicin mitigates cellular injury [25, 30]. The in vivo findings complement and extend these in vitro observations. The rats in the model group, which were induced with ethylene glycol and ammonium chloride, exhibited extensive calcium oxalate crystal deposition, tubular degeneration, and interstitial inflammation-pathological features characteristic of nephrolithiasis [31]. The allicin group presented reduced calcium deposition, which was consistent with the improvement in renal tissue pathological injury. These findings indicate that allicin may reduce physical stimulation and chemical damage to renal tubular epithelial cells by decreasing the formation and deposition of calcium oxalate crystals, thereby blocking the vicious cycle of “crystal deposition-inflammatory response-tissue injury”. Such sequential disruption interrupts the self‑sustaining pathological cascade: calcium oxalate deposition triggers inflammatory activation, which further worsens tubular damage and enhances crystal adhesion; intensified crystal aggregation then exaggerates local inflammation, ultimately driving stone formation and progression. This result is consistent with the inhibitory effect on the TNF/NF-κB pathway: reduced inflammation may decrease the adhesion ability of renal tubular epithelial cells to crystals, whereas reduced crystal deposition further decreases the release of inflammatory factors, collectively promoting the recovery of renal tissue function. Notably, the consistency between the in vitro and in vivo results strengthens the mechanistic link: allicin-mediated inhibition of TNF/NF-κB signaling likely reduces both tubular epithelial damage (limiting crystal adhesion) and inflammatory cell infiltration (preventing interstitial fibrosis), collectively mitigating stone progression. This finding aligns with broader evidence that anti-inflammatory strategies disrupt the vicious cycle of crystal deposition, inflammation, and tissue injury in kidney stone disease [32]. The present study also highlights allicin within the growing body of research on natural compounds for kidney stone prevention. For example, epigallocatechin-3-gallate has been shown to inhibit stone formation by reducing oxidative stress [33–35], while caffeine decreases calcium oxalate binding to renal epithelial cells [36, 37]. The mechanism of allicin, which is centered on TNF/NF-κB inhibition, adds a new dimension to this field, highlighting its anti-inflammatory activity as a key therapeutic target. Notably, the present study still has several inherent limitations. First, the in vivo histological analysis was performed with only 3 rats per group, which is a relatively small sample size and may weaken statistical robustness and representativeness. To compensate for the limited number of animals, we randomly selected and quantitatively analyzed multiple high-power fields (HPFs) per section and used the mean value for statistical evaluation, which increased the number of data collection points and improved the reliability of histological observations. To enhance the reliability of subsequent verification, future studies should expand the sample size to 6–8 rats per group and combine quantitative methods such as crystal counting and immunohistochemical detection of inflammatory markers. Second, the present study is predominantly limited to histological observations, and the specific molecular mechanisms underlying the protective effects of allicin, beyond its general anti-inflammatory response, remain insufficiently explored. Further downstream targets of the TNF/NF-κB pathway were not identified, and the regulatory effect of this pathway was not verified through gene knockdown or pathway-specific inhibitor assays. Relevant supplementary experiments should be carried out in follow-up research to further enrich and confirm the internal regulatory mechanism. Third, the in vitro dose of 200 µM and in vivo dose of 50 mg/kg used here are experimental effective doses, which may not reflect clinically achievable plasma levels. Allicin possesses low bioavailability and fast in vivo metabolism, and relevant pharmacokinetic data are currently missing. Subsequent studies will utilize high-performance liquid chromatography (HPLC) and mass spectrometry to explore dosage optimization and pharmacokinetic characteristics, providing better evidence for clinical translation. Moreover, allicin has low oral bioavailability and rapid in vivo metabolism, which may limit its clinical efficacy; future studies should focus on structural modification, nano‑formulation, or optimized administration routes to improve its pharmacokinetic profiles and translational potential. Despite these limitations, the present study provides a compelling preclinical rationale for allicin as a therapeutic agent for kidney stones. Its ability to target the TNF/NF-κB pathway, reduce inflammation, and preserve renal structure warrants further investigation. Future directions could include dose‒response studies to optimize allicin administration, combination therapies with existing drugs to increase efficacy, and mechanistic studies on the impact of allicin on renal transporters involved in oxalate excretion. Conclusion This research comprehensively assessed the therapeutic value and mechanistic basis of allicin in mitigating kidney stone formation via an integrated approach. Network pharmacology identified TNF-α as a core target and the TNF signaling pathway as a key pathway involved in the anti-kidney stone effects of allicin. Molecular docking confirmed the potential binding between allicin and TNF, laying a structural foundation for their interaction. In vitro experiments confirmed that allicin can protect HK-2 cells from calcium oxalate-induced injury by regulating the TNF/NF-κB signaling pathway and reducing inflammation and apoptosis. In vivo experiments further demonstrated that allicin alleviates renal tissue damage in a rat model of kidney stones, with effects similar to those of the positive control drug. These results collectively indicate that allicin exerts antikidney stone effects through a multitarget and multipathway mechanism, mainly by inhibiting the TNF/NF-κB signaling pathway to reduce renal inflammation, mitigate tubular injury, and decrease calcium oxalate crystal deposition. This study provides preclinical evidence to support the rationale for continued research into the role of allicin in kidney stone prevention and treatment, with further studies needed to evaluate its translational potential in clinical settings. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements We would like to thank the Ethics Committee of Hainan Medical University for their guidance and approval of this study. Author contributions ZP and MX contributed equally to this work. SH and ZP conceived and designed the study. ZP, MX, and JY performed the experiments. ZP and MX analyzed the data and wrote the manuscript. SH revised the manuscript. All authors read and approved the final manuscript. Funding This study was supported by the Joint Program on Health Science & Technology Innovation of Hainan Province (Grant No. WSJK2025QN078). Data availability The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate The experimental protocol was approved by the Ethics Committee of Hainan Medical University (Approval No. HYLL-2024-614). All animal experiments were performed in accordance with the relevant guidelines and regulations for the care and use of laboratory animals. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Zechun Peng and Mingbin Xu contributed equally to this work. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.